Skip to content

Clinical effects of Xingxiao Pill in the treatment of cancer

Clinical effects of Xingxiao Pill in the treatment of cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000004184
Enrollment
Unknown
Registered
2020-09-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

treatment group:Routine treatment after chemotherapy + Xingxiao pill by mouth
control group:Routine treatment after chemotherapy

Sponsors

Dongfang Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients will be diagnosed as malignant tumors with cytological or histopathological diagnosis , including respiratory tract tumors, gastrointestinal tumors and reproductive system tumors; 2) Patients who have received chemotherapy in the past 1 month; 3) Aged >= 18 years; 4) Eastern Cooperative Oncology Group (ECOG) score 1 month; 5) Have certain reading ability; 6) Voluntarily agree to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Hyperthermia occurs within two weeks with a body temperature of more than 38 degrees C, or there is obvious active infection; 2) Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, grade 2 or above heart disease or uncontrolled hypertension before enrollment (systolic blood pressure over 160 mmHg or diastolic blood pressure over 100mmHg); 3) Serum bilirubin is 1.5 times higher than the upper limit of the reference range of normal value; 4) The serum myoliver is 1.5 times higher than the upper limit of the reference range of normal value or myoliver clearance rate in the absence of liver metastasis; 2.5 times the upper limit of the normal value, or 5 times the upper limit of the reference range of ALT or AST in the case of liver metastasis; 6) Pregnant or lactating women; 7) Persons with mental illness or intellectual or language impairment; 8) Patients who are known to be allergic to the components used in the study; 9) Patients who are participating in other drug trials within the past month or so;

Design outcomes

Primary

MeasureTime frame
TCM syndrome score and chills and fever constitution scale;

Secondary

MeasureTime frame
Objective Response Rate;stool routine test;electrocardiogram;Blood coagulation;blood routine examination;Quality of Life scale;Biochemical;routine urine test;tumor CT enhancement;

Countries

China

Contacts

Public ContactZhou Tian

Beijing University of Chinese Medicine

zhoutian_med@163.com+86 13466611847

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026